Ms
Punita
Shah

Patent Director

Manchester Office

Life sciences

Telephone. +44(0) 161 247 4900
Mobile. +44(0) 796 854 3578
Email. [email protected]

Experience

Punita's expertise lies predominantly in the area of biotechnology, with a specific focus on the technical fields of Agbio, diagnostics including point of care lateral flow tests, personalized medicine, biologics and gene therapy. Her experience also includes leading multi-disciplinary teams handling innovations which span the life sciences and electronics sectors. At both a personal and professional level, Punita is keenly interested in sustainable technology, in particular the ways in which the life sciences sector can improve sustainability to address key problems such as plastic pollution, packaging and the food industry.

Punita has worked extensively with multinational corporations, universities, and small to medium sized enterprises. She has a practical and commercially focused approach, and over the course of her career has assisted numerous small companies with IP portfolio management, with a focus toward building a robust patent strategy.

Punita is highly experienced in obtaining commercially valuable patent protection for her clients. Her practice includes routinely managing large global patent portfolios, as well as conducting due diligence to support corporate acquisition and investment, conducting freedom to operate analysis, and advising her clients on third party rights and infringement. Punita has defended her clients patent rights and commercial position in leading opposition and appeal proceedings before the EPO.

Qualifications

Patent Attorney

Chartered (UK)
European


MA

MA (Cantab) Natural Sciences

Conferences: 2020

November 16th 2020

CIPA Life Sciences conference 2020

Attended

Related News

Artificial intelligence inventions in healthcare – can you patent them in Europe?

Artificial Intelligence (AI) has moved from the realm of science fiction firmly into the mainstream of technological innovation. Trained AI models in some cases are able to perform data analysis …

Read article

Patenting digital mental health

Mental health and behavioural disorders have a profound impact on wellbeing worldwide, with an estimated 13% of the global population suffering from a mental health or substance use disorder [1]. …

Read article

Patenting antibodies in the US and Europe

Is the USPTO now stricter than the EPO on antibody claims? A consideration of recent developments from both sides of the pond. Patent protection for monoclonal antibodies, bispecific antibodies and …

Read article

Patentability of Simulations in Europe

Simulations offer a powerful tool in modern-day engineering. Subjecting designs to initial testing in a simulated environment will, for many designs, reduce costs owing to reduced needs to produce and …

Read article

Blockbuster blood thinning patent revoked

Summary Mr Justice Meade has revoked Bristol Myers Squibb’s (BMS) European patent No. EP1427415 (EP’415) and corresponding supplementary protection certificate (SPC) that relate to the compound Apixaban (ELIQUIS) for lack …

Read article
Event - 10th May 2022

The HGF IP in Healthcare Conference 2022

After a challenging couple of years, we are delighted to invite you to join us for HGF’s eighth annual IP in Healthcare Conference. We will review the latest intellectual property …

Event details
Event - 10th May 2022

HGF UPC events in Germany and Austria 2022

HGF is holding a webinar and an in-person event covering the UPC in Germany and Austria this Spring. The provisional phase of the Unified Patent Court (UPC) is now underway …

Event details
Event - 23rd March 2022

HGF webinar: Getting your first filing right

HGF hosted a webinar on Wednesday 23rd March on Getting your first filing right. One of the most often asked questions of patent attorneys is: “when should we file?” Both …

Event details

Let's talk

If you would like to discuss how HGF could help you, contact one of our IP specialists.